Search

everythinglearnresearchcommunity

for

Search:↓

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

A new genetic disorder caused by an ODC1 mutation can be treated with DFMO.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

Aumolertinib effectively controls lung cancer and improves quality of life.

A skin condition called pyodermatitis vegetans was found in a patient with multiple myeloma for the first time.

AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.

DFMO treatment improves hair growth, muscle tone, and development in Bachmann-Bupp syndrome patients.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Upadacitinib improved multiple immune-related conditions in one patient.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Polyamines are crucial for skin tumor development, and inhibiting them can prevent tumors.

Cepharanthine shows promise as a natural anticancer treatment.

YH0618 helps reduce chemotherapy-induced hair loss by targeting specific proteins and pathways.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

The committee decided not to approve the drug due to low effectiveness and high risks.

The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.

CXCL7 is essential for muscle repair by aiding early neutrophil infiltration.